|Founders||Leonard Guarente, Eric Marcotulli, Dan Alminana|
Elysium Health was founded in 2014 by biologist and director of the Glenn Center for Biology of Aging Research at MIT Leonard Guarente Ph.D., Dan Alminana, and Eric Marcotulli to develop health products based on advancements in scientific research market dietary supplements.
In 2015, the company launched publicly and introduced its first product, Basis, which contains nicotinamide riboside and pterostilbene. The company is widely described as being in the anti-aging field. Elysium is one of several companies founded at around the same time by people with backgrounds in the tech industry and Silicon Valley who saw opportunities in the health and biomedical industries, often focused on anti-aging.
In 2015, the company started selling Basis, a supplement designed to slow aging at the cellular level. In 2019, Elysium launched Index, a test that uses epigenetic analysis on saliva samples to calculate a biological age.
In 2020, Elysium launched a new supplement called Matter, a B-vitamin complex intended to slow brain atrophy as one ages, based on a study called VITACOG done at the University of Oxford.
Elysium originally bought the ingredients in Basis from ChromaDex, which as of December 2016, sold the two ingredients to other supplement companies that also marketed products containing them. The two companies had an agreement under which Elysium Health did not have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the VP of business development from ChromaDex and reportedly stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.
In September 2018, Dartmouth College and ChromaDex sued Elysium for infringing on patents for nicotinamide riboside. In August 2020, W.R. Grace and Company also sued Elysium for infringing on their patents for crystalline nicotinamide riboside. In September 2021, the claims by Dartmouth and ChromaDex were dismissed by a U.S. district judge, essentially invalidating their patents.
- Wallace, Benjamin (August 23, 2016). "An MIT scientist claims that this pill is the fountain of youth". New York Magazine.
- Weintraub, Karen (February 3, 2015). "The anti-aging pill". MIT Technology Review. Retrieved 5 February 2015.
- Friend, Tad (April 3, 2017). "Silicon Valley's quest to live forever". The New Yorker.
- de Magalhães, JP; Stevens, M; Thornton, D (November 2017). "The business of anti-aging science". Trends in Biotechnology. 35 (11): 1062–1073. doi:10.1016/j.tibtech.2017.07.004. PMID 28778607.
- "The Anti-Aging Pill". MIT Technology Review. Retrieved 2021-09-09.
- "Elysium Review | Are their supplements and age tests legit?". Innerbody. Retrieved 2021-09-09.
- Harris, Ainsley (2019-11-04). "How old are you really? Elysium Health will tell you—for $500". Fast Company. Retrieved 2021-09-10.
- nutraingredients-usa.com. "Elysium launches supplement aimed at slowing brain atrophy". nutraingredients-usa.com. Retrieved 2021-10-28.
- Weintraub, Karen (January 6, 2017). "Critics blast star-studded advisory board of anti-aging company". MIT Technology Review.
- Vinluan, Frank (6 December 2016). "First clinical trial done, Elysium lands $20M for health supplements". Xconomy.
- Zhang, Sarah (July 6, 2016). "The weird business behind a trendy "anti-aging" pill". Wired.
- Lowe, Derek (25 April 2016). "Subtle changes can be yours, for fifty dollars a month". In the Pipeline.
- Buhr, Sarah (January 16, 2017). "A new lawsuit alleges anti-aging startup Elysium Health hasn't paid its sole supplier". TechCrunch.
- Schultz, Hank. "ChromaDex, Elysium lock horns over outcome of appeals court decision on nicotinamide riboside patents". NutraIngredients-USA. Retrieved 2021-01-01.
- Yasiejko, Christopher. "W.R. Grace Sues Elysium for Patent Damages on Dietary Supplement". Bloomberg Law. Retrieved 2021-01-01.
- "Jury verdict tilts toward Elysium Health in dispute with ChromaDex, court records show". Natural Products INSIDER. 2021-09-29. Retrieved 2021-10-30.